PR: Heidelberg Pharma and Partner Magenta to Present Initial Clinical Data on their Antibody Drug Conjugates at the ASH Annual Meeting 2022

• Heidelberg Pharma presents initial findings of the first in human study with ATAC^® candidate HDP-101
• Licensing partner Magenta presents initial data from Phase I/II study with ATAC^® candidate MGTA-117

Ladenburg, Germany, 10 November 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that it will present initial data from the Phase I/IIa clinical trial with HDP-101 at the 64^th Annual Meeting of the American Society of Hematology (ASH). In addition, partner Magenta Therapeutics, Cambridge, MA, USA, (Magenta) (NASDAQ: MGTA) will present data from its clinical trial with MGTA-117. The conference will take place from December 10 to 13, 2022 in New Orleans, USA.

Dr. András Strassz, Chief Medical Officer of Heidelberg Pharma AG, commented: "We are excited to present initial safety data of the first in human study with HDP-101, an Antibody Drug Conjugate with the highly potent payload Amanitin, at the ASH meeting. Up to now, HDP‑101 has shown good tolerability in late stage relapsed and/or refractory multiple myeloma patients. The study is currently enrolling patients in the third cohort and we are curious to see further safety and efficacy data.”

Poster title: HDP-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study

Presentation details

Abstract #3219

Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II

Time and location: Sunday, December 11, 2022, 6:00pm - 8:00pm CST, Hall D (Ernest N. Morial Convention Center)

Dr. Strassz will present the poster showing initial clinical data of the ongoing open-label, multi-center Phase I/IIa trial evaluating HDP-101 in multiple myeloma. He will also be available to answer questions.

HDP-101 is a BCMA antibody-Amanitin conjugate for the treatment of relapsed or refractory multiple myeloma, a bone marrow cancer with high unmet medical need. The first part of the ongoing trial is a Phase I dose escalation study to determine an optimal and safe dose of HDP-101 for the Phase II part of the study. It is planned to treat up to 36 patients who will receive HDP‑101 intravenously every 3 weeks. During this part of the trial, tolerability of different dose levels will be evaluated.

Oral presentation from Heidelberg Pharma’s licensing partner Magenta

Presentation title: MGTA-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study

Presentation details

Abstract #874

Session: 701. Experimental Transplantation: Basic and Translational: Poster III

Time and location: Monday, December 12, 2022, 3.30pm CST

Poster presentations from Heidelberg Pharma’s licensing partner Magenta

Poster title: The Pharmacokinetic and Pharmacodynamic Characterization of MGTA-117, an Anti-CD117-Amanitin Antibody-Drug Conjugate for Targeted Conditioning Prior to Transplant, in Non-Human Primates

Presentation details

Abstract #4592

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I

Time and location: Monday, December 12, 2022, 6:00-8:00 pm CST, Hall D (Ernest N. Morial Convention Center)

All abstracts and further information will be available online on the ASH conference website.